{"title":"奥马珠单抗治疗妊娠期慢性自发性荨麻疹1例报告及文献复习","authors":"A. Salman, Meryem Aktas","doi":"10.21911/aai.599","DOIUrl":null,"url":null,"abstract":"ABSTRACT Omalizumab is a safe and effective treatment option for chronic spontaneous urticaria (CSU). Although cohort studies in patients with asthma show no increased risk of congenital abnormalities, very little data exist in the literature regarding the use of omalizumab for CSU during pregnancy. Herein, the safe and successful use of omalizumab updosing in a pregnant woman with CSU along with a review of the published literature is presented. Keywords: Chronic spontaneous urticaria, omalizumab, pregnancy, updosing","PeriodicalId":42004,"journal":{"name":"Astim Allerji Immunoloji","volume":" ","pages":""},"PeriodicalIF":0.3000,"publicationDate":"2021-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Omalizumab Treatment in Chronic Spontaneous Urticaria During Pregnancy: Report of A Case and Review of the Literature\",\"authors\":\"A. Salman, Meryem Aktas\",\"doi\":\"10.21911/aai.599\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"ABSTRACT Omalizumab is a safe and effective treatment option for chronic spontaneous urticaria (CSU). Although cohort studies in patients with asthma show no increased risk of congenital abnormalities, very little data exist in the literature regarding the use of omalizumab for CSU during pregnancy. Herein, the safe and successful use of omalizumab updosing in a pregnant woman with CSU along with a review of the published literature is presented. Keywords: Chronic spontaneous urticaria, omalizumab, pregnancy, updosing\",\"PeriodicalId\":42004,\"journal\":{\"name\":\"Astim Allerji Immunoloji\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.3000,\"publicationDate\":\"2021-03-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Astim Allerji Immunoloji\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.21911/aai.599\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Astim Allerji Immunoloji","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21911/aai.599","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ALLERGY","Score":null,"Total":0}
Omalizumab Treatment in Chronic Spontaneous Urticaria During Pregnancy: Report of A Case and Review of the Literature
ABSTRACT Omalizumab is a safe and effective treatment option for chronic spontaneous urticaria (CSU). Although cohort studies in patients with asthma show no increased risk of congenital abnormalities, very little data exist in the literature regarding the use of omalizumab for CSU during pregnancy. Herein, the safe and successful use of omalizumab updosing in a pregnant woman with CSU along with a review of the published literature is presented. Keywords: Chronic spontaneous urticaria, omalizumab, pregnancy, updosing
期刊介绍：
Asthma Allergy Immunology has been published three times a year in April, August and December as the official and periodical journal of the Turkish National Society of Allergy and Clinical Immunology since 2003. All articles published in the journal have been available online since 2003. A peer reviewed system is used in evaluation of the manuscripts submitted to Asthma Allergy Immunology. The official language of the journal is English. The aim of the journal is to present advances in the field of allergic diseases and clinical immunology to the readers. In accordance with this goal, manuscripts in the format of original research, review, case report, articles about clinical and practical applications and editorials, short report and letters to the editor about allergic diseases and clinical immunology are published in the journal. The target reader population of the Asthma Allergy Immunology includes specialists and residents of allergy and clinical immunology, pulmonology, internal medicine, pediatrics, dermatology and otolaryngology as well as physicians working in other fields of medicine interested in allergy and immunological diseases.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
